


Please Direct All Correspondence to Customer Number 20995



TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT

Applicant : Gamble et al.
App. No : 10/526,812
Filed : March 4, 2005
For : A METHOD OF MODULATING
ENDOTHELIAL CELL ACTIVITY
Examiner : Not Yet Assigned
Art Unit : Not Yet Assigned

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 5, 2005

(Date)

Eric S. Furman, Reg. No. 45,664

Mail Stop Amendment

Commissioner for Patents


P.O. Box 1450


Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing (38) references.
 - (X) Enclosing (35) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Eric S. Furman
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Gamble et al.
App. No : 10/526,812
Filed : March 4, 2005
For : A METHOD OF MODULATING
ENDOTHELIAL CELL ACTIVITY
Examiner : Not Yet Assigned
Art Unit : Not Yet Assigned

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 5, 2005

(Date)


Eric S. Furman, Reg. No. 45,664

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing (38) references to be considered by the Examiner. Also enclosed are (35) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: December 5, 2005


By: 
Eric S. Furman
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 3

Application No.	10/526,812
Filing Date	March 4, 2005
First Named Inventor	Jennifer Rut Gamble
Art Unit	Not Yet Assigned
Examiner	Not Yet Assigned
Attorney Docket No.	DAVI253.001APC



U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,410,597	06-25-2002	Bieberich et al.	
	2	5,763,263	06-09-1998	Dehlinger	
	3	2002/0091082A1	07-11-2002	Aiello	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	4	Battle et al., (1994) Antipeptide antibodies directed against the C ζ (PKC ζ) react with a Ca ²⁺ - and TPA-sensitive PKC in HT-29 human intestinal epithelial cells.	
	5	Bunin BA, et al. (1994) <i>Proc. Natl. Acad. Sci. USA</i> , 91:4708-4712.	
	6	Bussolino F, Silvagno F, Garbarino G, Costamagna C, Sanavio F, Arese M, Soldi R, Aglietta M, Pescarmona G, Camussi G, et al. (1994) <i>J Biol Chem.</i> 269:2877-86.	
	7	Chou, M.M., Hou, W., Johnson, J., Graham, L.K., Lee, M.H., Chen, C.S., Newton, A.C., Schaffhausen, B.S., Toker, A. (1998) <i>Curr Biol.</i> 8:1069-77.	
	8	Coughlin, S.R. (2000) <i>Nature</i> 407:258-64.	
	9	DeWitt SH, et al. (1993) <i>Proc. Natl. Acad. Sci. USA</i> , 90:6909-6913.	
	10	Draijer, R., Atsma, D.E., van der Laarse, A., van Hinsberg, V.W. (1995) <i>Circ Res.</i> 76:199-208.	
	11	Dvorak, H.F., Harvey, V.S., Estrella, P., Brown, L.F., McDonagh, J., Dvorak, A.M. (1987) <i>Lab Invest.</i> 57:673-86.	
	12	Dvorak, H.F., Brown, L.F., Detmar, M., Dvorak, A.M. (1995) <i>Am J Pathol.</i> 146:1029-39.	
	13	Frey et al., (2002) PK C ζ regulates TNF- α -induced activation of NADPH oxidase in endothelial cells. <i>Circulation Research</i> 90:1012-1019.	
	14	Gamble, J.R., Drew, J., Trezise, L., Underwood, A., Parsons, M., Kasminkas, L., Rudge, J., Yancopoulos, G., Vadas, M.A. (2000) <i>Circ Res.</i> 87:603-7.	
	15	Garcia, J.G., Verin, A.D., Schaphorst, K.L. (1996) <i>Semin Thromb Hemost.</i> 22:309-15.	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 2 OF 3

Application No.	10/526,812
Filing Date	March 4, 2005
First Named Inventor	Jennifer Rut Gamble
Art Unit	Not Yet Assigned
Examiner	Not Yet Assigned
Attorney Docket No.	DAVI253.001APC

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	16	Hempel et al., (1999) Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. <i>Circulation</i> 99(19):2523-2529.	
	17	Kobayashi, E., Nakano, H., Morimoto, M., Tamaoki, T. (1989) <i>Biochem Biophys Res Commun.</i> 159:548-53.	
	18	Laudanna, C., Mochly-Rosen, D., Liron, T., Constantin, G., Butcher, E.C. (1998) <i>J Biol Chem.</i> 273:30306-15.	
	19	Le Good, J.A., Ziegler, W.H., Parekh, D.B., Alessi, D.R., Cohen, P., Parker, P.J. (1998) <i>Science</i> 281:2042-5.	
	20	Li, H., Ohrlein, S.A., Wallerath, T., Ihrig-Biedert, I., Wohlfart, P., Ulshofer, T., Jessen, T., Herget, T., Forstermann, U., Kleinert, H. (1998) <i>Mol Pharmacol.</i> 53:630-7.	
	21	Litwin, M., Clark, K., Noack, L., Furze, J., Berndt, M., Albelda, S., Vadas, M., Gamble, J. (1997) <i>J Cell Biol.</i> 139:219-28.	
	22	Lum, H., Andersen, T.T., Siflinger-Birnboim, A., Tiruppathi, C., Goligorsky, M.S., Fenton, J.W. 2nd, Malik, A.B. (1993) <i>J Cell Biol.</i> 120:1491-9.	
	23	Lynch JJ, Ferro TJ, Blumenstock FA, Brockenauer AM, Malik AB. (1990) <i>J Clin Invest.</i> 85:1991-8.	
	24	Macfarlane, S.R., Seatter, M.J., Kanke, T., Hunter, G.D., Plevin, R. (2001) <i>Pharmacol Rev.</i> 53:245-82.	
	25	Martiny-Baron, G., Kazanietz, M.G., Mischak, H., Blumberg, P.M., Kochs, G., Hug, H., Marme, D., Schachtele, C. (1993) <i>J Biol Chem.</i> 268:9194-7.	
	26	Mattila et al., (1994) Expression of six protein kinase C isotypes in endothelial cells, <i>Life Sciences</i> 55(16):1253-1260.	
	27	The Merck Index (12 th ed). Published by Merck & Co., Inc. Entry 886: Aspirin.	
	28	Nishizuka, Y. (2001) <i>Alcohol Clin Exp Res.</i> 25:3S-7S.	
	29	Papapetropoulos, A., Garcia-Cardena, G., Dengler, T.J., Maisonnier, P.C., Yancopoulos, G.D. and Sessa, W.C. (1999) <i>Lab Invest.</i> 70:213-23.	
	30	Parekh, D.B., Ziegler, W., Parker, P.J. (2000) <i>Embo J.</i> 19:496-503.	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/526,812
Filing Date	March 4, 2005
First Named Inventor	Jennifer Rut Gamble
Art Unit	Not Yet Assigned
Examiner	Not Yet Assigned
Attorney Docket No.	DAVI253.001APC

(Multiple sheets used when necessary)

SHEET 3 OF 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	31	Rahman et al., (2000) Protein kinase C- ζ mediates TNF- α -induced ICAM-1 gene transcription in endothelial cells. American Journal of Physiology. Cell Physiology 279:C906-C914.	
	32	Uberall, F., Hellbert, K., Kampfer, S., Maly, K., Villunger, A., Spitaler, M., Mwanjewe, J., Baier-Bitterlich, G., Baier, G., Grunicke, H.H. (1999) <i>J Cell Biol.</i> 144:413-25.	
	33	van Nieuw Amerongen GP, Draijer R, Vermeer MA, van Hinsbergh VW. (1998) <i>Circ Res.</i> 83:1115-23.	
	34	Vouret-Craviari V, Boquet P, Pouyssegur J, Van Obberghen-Schilling E. (1998) <i>Mol Biol Cell.</i> 9:2639-53.	
	35	Wellner et al., (1999) The proliferative effect of vascular endothelial growth factor requires protein kinase C- α and protein kinase C ζ . Arteriosclerosis, Thrombosis and Vascular Biology 19(1): 178-185.	
	36	Yamada Y, Furumichi T, Furui H, Yokoi T, Ito T, Yamauchi K, Yokota M, Hayashi H, Saito H. (1990) <i>Arteriosclerosis</i> 10:410-20.	
	37	Zhou G, Wooten MW, Coleman ES. (1994) <i>Exp Cell Res.</i> 214:1-11.	
	38	Internacional Search Report corresponding to International Application No. PCT/AU03/01154 dated November 13, 2003.	

2165502
120505

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.